Private Advisor Group LLC Makes New Investment in Elanco Animal Health Incorporated (NYSE:ELAN)

Private Advisor Group LLC acquired a new position in Elanco Animal Health Incorporated (NYSE:ELAN) during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 128,171 shares of the company’s stock, valued at approximately $1,205,000.

Several other hedge funds have also bought and sold shares of ELAN. Quadrant Capital Group LLC boosted its position in Elanco Animal Health by 281.7% in the 4th quarter. Quadrant Capital Group LLC now owns 2,706 shares of the company’s stock worth $33,000 after purchasing an additional 1,997 shares in the last quarter. Ellevest Inc. raised its stake in shares of Elanco Animal Health by 38.0% during the 1st quarter. Ellevest Inc. now owns 4,406 shares of the company’s stock worth $41,000 after buying an additional 1,213 shares during the period. EverSource Wealth Advisors LLC raised its stake in shares of Elanco Animal Health by 381.1% during the 4th quarter. EverSource Wealth Advisors LLC now owns 4,229 shares of the company’s stock worth $52,000 after buying an additional 3,350 shares during the period. Captrust Financial Advisors raised its stake in shares of Elanco Animal Health by 57.0% during the 1st quarter. Captrust Financial Advisors now owns 2,690 shares of the company’s stock worth $70,000 after buying an additional 977 shares during the period. Finally, DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main acquired a new position in shares of Elanco Animal Health during the 4th quarter worth approximately $70,000. Hedge funds and other institutional investors own 95.29% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms recently commented on ELAN. Piper Sandler increased their price objective on Elanco Animal Health from $9.00 to $13.00 and gave the company a “neutral” rating in a research note on Monday, August 14th. The Goldman Sachs Group increased their price objective on Elanco Animal Health from $8.50 to $9.50 and gave the company a “sell” rating in a research note on Tuesday, August 8th. One research analyst has rated the stock with a sell rating, four have issued a hold rating and one has assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $15.10.

Elanco Animal Health Stock Up 3.0 %

Shares of NYSE:ELAN opened at $12.20 on Tuesday. The company has a quick ratio of 1.53, a current ratio of 2.84 and a debt-to-equity ratio of 0.81. The business has a fifty day moving average of $11.24 and a two-hundred day moving average of $10.29. The stock has a market cap of $6.01 billion, a P/E ratio of -61.00, a PEG ratio of 7.92 and a beta of 1.01. Elanco Animal Health Incorporated has a 52-week low of $7.88 and a 52-week high of $16.14.

Elanco Animal Health (NYSE:ELAN) last issued its earnings results on Monday, August 7th. The company reported $0.18 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.05 by $0.13. The company had revenue of $1.06 billion during the quarter, compared to analysts’ expectations of $1.04 billion. Elanco Animal Health had a positive return on equity of 6.93% and a negative net margin of 2.24%. The firm’s quarterly revenue was down 10.2% on a year-over-year basis. During the same period in the prior year, the business earned $0.36 EPS. On average, research analysts expect that Elanco Animal Health Incorporated will post 0.85 earnings per share for the current year.

Elanco Animal Health Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.